Clinical significance of BRCA1 and BRCA2 mRNA and protein expression in patients with sporadic gastric cancer

Kim,Hee  Sung; Hwang,In  Gyu; Min,Hye  Young; Bang,Yung‑Jue; Kim,Woo  Ho

doi:10.3892/ol.2019.10132

Clinical significance of BRCA1 and BRCA2 mRNA and protein expression in patients with sporadic gastric cancer

Authors:
- Hee Sung Kim
- In Gyu Hwang
- Hye Young Min
- Yung‑Jue Bang
- Woo Ho Kim
View Affiliations

Affiliations: Department of Pathology, Chung‑Ang University College of Medicine, Seoul 06974, Republic of Korea, Department of Internal Medicine, Chung‑Ang University College of Medicine, Seoul 06974, Republic of Korea, Department of Pharmacy, Chung‑Ang University College of Pharmacy, Seoul 06974, Republic of Korea, Department of Internal Medicine, Seoul National University College of Medicine, Seoul 110‑799, Republic of Korea, Department of Pathology, Seoul National University College of Medicine, Seoul 110‑799, Republic of Korea
Published online on: March 8, 2019 https://doi.org/10.3892/ol.2019.10132
Pages: 4383-4392

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of the present study was to investigate the clinical significance of BRCA1/BRCA2 DNA repair associated (BRCA1/BRCA2) gene expression in patients with sporadic gastric cancer (GC) who had received postoperative adjuvant chemotherapy. Breast cancer type 1 and 2 susceptibility protein (BRCA1 and BRCA2) expression and BRCA1/BRCA2 mRNA expression were evaluated using immunohistochemistry (IHC) and in‑situ hybridization (ISH) on tissue GC microarray tissues, in addition to reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). The results were analyzed for clinicopathological associations. A total of 367 cases of sporadic GC (stages II and III) were subjected to BRCA1 and BRCA2 expression analysis, and for BRCA1 and BRCA2 IHC, 360 cases were informative. A total of 61 cases (16.9%) displayed a loss of BRCA1 and 63 (17.5%) displayed a loss of BRCA2. BRCA1 and BRCA2 ISH results were obtained in 364 cases, of which 98 (26.9%) presented with low expression of BRCA1 mRNA and 148 (40.7%) with low expression of BRCA2 mRNA. In 72 of the 367 cases, BRCA1 and BRCA2 mRNA expression levels were assessed using RT‑qPCR, of which 50 (69.4%) and 56 (77.8%) displayed low expression of BRCA1 and BRCA2, respectively. Positive IHC expression of BRCA2 was associated with advanced tumor stage; however, BRCA1 expression was not associated with any clinicopathological parameters. Associations between the RT‑qPCR and ISH methods were not significant for either BRCA1 or BRCA2. The results of Kaplan‑Meier survival analysis with stage subgrouping revealed no significant differences with regard to survival rate. Of the multivariate analyses, neither BRCA1 nor BRCA2 IHC results were independent prognostic factors. In summary, the present study indicated that BRCA1 and BRCA2, as assessed by IHC, may be used as clinicopathological biomarkers to evaluate the prognosis of sporadic GC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Wang J, Li X, Li J, Zhou L, Qiu T, Zhang M and Liu P: Prognostic significance of BRCA1 expression in gastric cancer. Med Oncol. 30:4232013. View Article : Google Scholar : PubMed/NCBI
3	Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL and Weber BL: Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 94:1365–1372. 2002. View Article : Google Scholar : PubMed/NCBI
4	Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu L, Wang T and Liu B: ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer. 8:972008. View Article : Google Scholar : PubMed/NCBI
5	Semba S, Yokozaki H, Yasui W and Tahara E: Frequent microsatellite instability and loss of heterozygosity in the region including BRCA1 (17q21) in young patients with gastric cancer. Int J Oncol. 12:1245–1251. 1998.PubMed/NCBI
6	Shim HJ, Yun JY, Hwang JE, Bae WK, Cho SH, Lee JH, Kim HN, Shin MH, Kweon SS, Lee JH, et al: BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Sci. 101:1247–1254. 2010. View Article : Google Scholar : PubMed/NCBI
7	Goffin JR, Chappuis PO, Bégin LR, Wong N, Brunet JS, Hamel N, Paradis AJ, Boyd J and Foulkes WD: Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer. 97:527–536. 2003. View Article : Google Scholar : PubMed/NCBI
8	Kennedy RD, Quinn JE, Mullan PB, Johnston PG and Harkin DP: The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst. 96:1659–1668. 2004. View Article : Google Scholar : PubMed/NCBI
9	Reguart N, Cardona AF, Carrasco E, Gomez P, Taron M and Rosell R: BRCA1: A new genomic marker for non-small-cell lung cancer. Clin Lung Cancer. 9:331–339. 2008. View Article : Google Scholar : PubMed/NCBI
10	Aly A and Ganesan S: BRCA1, PARP, and 53BP1: Conditional synthetic lethality and synthetic viability. J Mol Cell Biol. 3:66–74. 2011. View Article : Google Scholar : PubMed/NCBI
11	Foulkes WD: BRCA1 and BRCA2: Chemosensitivity, treatment outcomes and prognosis. Fam Cancer. 5:135–142. 2006. View Article : Google Scholar : PubMed/NCBI
12	Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E, Barrowdale D, McGuffog L, et al: Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 307:382–390. 2012. View Article : Google Scholar : PubMed/NCBI
13	Kim JW, Cho HJ, Kim M, Lee KH, Kim MA, Han SW, Oh DY, Lee HJ, Im SA, Kim TY, et al: Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer. Cancer Chemother Pharmacol. 71:1435–1443. 2013. View Article : Google Scholar : PubMed/NCBI
14	Wei J, Costa C, Ding Y, Zou Z, Yu L, Sanchez JJ, Qian X, Chen H, Gimenez-Capitan A, Meng F, et al: mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. J Natl Cancer Inst. 103:1552–1556. 2011. View Article : Google Scholar : PubMed/NCBI
15	Zhang ZZ, Liu YJ, Yin XL, Zhan P, Gu Y and Ni XZ: Loss of BRCA1 expression leads to worse survival in patients with gastric carcinoma. World J Gastroenterol. 19:1968–1974. 2013. View Article : Google Scholar : PubMed/NCBI
16	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC cancer staging manual. 7th. France: Springer; 2010
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Tsibulak I, Wieser V, Degasper C, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Marth C, Fiegl H and Zeimet AG: BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer. Br J Cancer. 119:683–692. 2018. View Article : Google Scholar : PubMed/NCBI
19	Al-Mulla F, Abdulrahman M, Varadharaj G, Akhter N and Anim JT: BRCA1 gene expression in breast cancer: A correlative study between real-time RT-PCR and immunohistochemistry. J Histochem Cytochem. 53:621–629. 2005. View Article : Google Scholar : PubMed/NCBI
20	Garg K, Levine DA, Olvera N, Dao F, Bisogna M, Secord AA, Berchuck A, Cerami E, Schultz N and Soslow RA: BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. Am J Surg Pathol. 37:138–146. 2013. View Article : Google Scholar : PubMed/NCBI
21	Peshkin BN, Alabek ML and Isaacs C: BRCA1/2 mutations and triple negative breast cancers. Breast Dis. 32:25–33. 2010. View Article : Google Scholar : PubMed/NCBI
22	Galizia E, Giorgetti G, Piccinini G, Santinelli A, Loretelli C, Bianchi F, Gagliardini D, Carbonari G, Pisa E, Belvederesi L, et al: BRCA1 expression in triple negative sporadic breast cancers. Anal Quant Cytol Histol. 32:24–29. 2010.PubMed/NCBI
23	Wang GH, Zhao CM, Huang Y, Wang W, Zhang S and Wang X: BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers. Hum Pathol. 71:135–144. 2018. View Article : Google Scholar : PubMed/NCBI
24	Meijer TG, Verkaik NS, Sieuwerts AM, van Riet J, Naipal KAT, van Deurzen CHM, den Bakker MA, Sleddens HFBM, Dubbink HJ, den Toom TD, et al: Functional ex vivo assay reveals homologous recombination deficiency in breast cancer beyond BRCA gene defects. Clin Cancer Res. 24:6277–6287. 2018. View Article : Google Scholar : PubMed/NCBI
25	Clark-Knowles KV, O'Brien AM and Weberpals JI: BRCA1 as a therapeutic target in sporadic epithelial ovarian cancer. J Oncol. 2010:8910592010. View Article : Google Scholar : PubMed/NCBI
26	Pothuri B: BRCA1- and BRCA2-related mutations: Therapeutic implications in ovarian cancer. Ann Oncol. 24 Suppl 8:viii22–viii27. 2013. View Article : Google Scholar : PubMed/NCBI
27	Yang Q, Sakurai T, Mori I, Yoshimura G, Nakamura M, Nakamura Y, Suzuma T, Tamaki T, Umemura T and Kakudo K: Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer. 92:54–60. 2001. View Article : Google Scholar : PubMed/NCBI
28	Zhang Y, Wu H, Yang F, Ning J, Li M, Zhao C, Zhong S, Gu K and Wang H: Prognostic value of the expression of DNA repair-related biomarkers mediated by alcohol in gastric cancer patients. Am J Pathol. 188:367–377. 2018. View Article : Google Scholar : PubMed/NCBI
29	Yoshida K and Miki Y: Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 95:866–871. 2004. View Article : Google Scholar : PubMed/NCBI
30	Takata M, Tachiiri S, Fujimori A, Thompson LH, Miki Y, Hiraoka M, Takeda S and Yamazoe M: Conserved domains in the chicken homologue of BRCA2. Oncogene. 21:1130–1134. 2002. View Article : Google Scholar : PubMed/NCBI